Research programme: beta cell protection and regeneration therapeutics - DeveloGen

Drug Profile

Research programme: beta cell protection and regeneration therapeutics - DeveloGen

Alternative Names: KuStu 144; Pax4 functional agonist

Latest Information Update: 18 Jan 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DeveloGen
  • Class Azepines
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 06 Sep 2010 Discontinued - Preclinical for Type-1 diabetes mellitus in Germany (unspecified route)
  • 06 Sep 2010 Discontinued - Preclinical for Type-2 diabetes mellitus in Germany (unspecified route)
  • 02 Sep 2010 DeveloGen has been acquired by Evotec AG
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top